poisar

Stocks · News reference

8-K filing — CytoDyn Inc. (CYDY)

SEC EDGAR

Filed: 2026-10-19 AccNo: 0001175680-26-000038 Size: 16 MB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CYDY
Source
edgar
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer

    CytoDyn Inc. announced the appointment of Robert E. Hoffman as Chief Executive Officer effective October 20, 2026, replacing Dr. Jacob Lalezari who served in the role since November 2023. Dr. Lalezari will transition to Head of Research and Translational Sciences to focus on identifying new opportunities for leronlimab in solid-tumor oncology. The leadership change comes as CytoDyn prepares for its next phase of clinical development with focus on clinical results, regulatory progress, and strategic partnerships in 2027.

    CYDY